Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy

• Status: Completed
• Trial end date: 2017-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to analyze the variation of adiponectinemia and its molecular forms in RA patients receiving tocilizumab therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Criteria

Inclusion Criteria:

• Patients with a diagnosis of RA and requiring Tocilizumab therapy

• Subject has provided written informed consent

Exclusion Criteria:

• Corticosteroid therapy (10 mg/day of prednisone or equivalent)

• Pregnant or lactating women

• Uncontrolled type 1 or type 2 diabetes

• Uncontrolled dyslipidemia

• Elevated transaminases (> three times higher than the normal range)

• History of diverticulitis or intestinal perforation

• Tocilizumab contraindications: Severe or active infections, Hypersensitivity to the active substance or to any of the excipients